CTI announces preclinical study of Pixuvri, provides mechanism for lower ... pharmabiz.com The EMA Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after one to three prior ... |
